CSL Limited believes the Government should fund a program to protect boys from Human Papillomavirus (HPV) after its vaccine, Gardasil, was approved for use in males.
Following the decision from the Therapeutic Goods Administration (TGA) to extend its indication for Gardasil to males aged nine to 26, CSL submitted an application for Government funding through the National Immunisation Program (NIP) for a gender neutral vaccination program.
The TGA approval coincided with the publication of a study in The Lancet, which revealed vaccinating males against HPV types 16 and 18 was a cost-effective way of preventing genital warts and anal cancers in men who have sex with men (MSM).
The research supported a vaccine program, but it did not conclude that introducing a similar...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.